Skip to main content
Journal cover image

Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.

Publication ,  Journal Article
Gonzalez-Gronow, M; Grenett, HE; Gawdi, G; Pizzo, SV
Published in: Exp Cell Res
February 1, 2005

Previous studies demonstrate that one of the six plasminogen type 2 glycoforms, plasminogen 2epsilon, enhances invasiveness of the 1-LN human prostate tumor cell line in an in vitro model. Binding of plasminogen 2epsilon to CD26 on the cell surface induces a Ca(2+) signaling cascade which stimulates the expression of matrix metalloproteinase-9, required by these cells to invade Matrigel. We now report that angiostatin, a fragment derived from plasminogen which prevents endothelial cell proliferation, is also a potent, direct inhibitor of 1-LN tumor cell invasiveness. We studied the effect of individual plasminogen 2 glycoform-derived angiostatins and found that only angiostatin 2epsilon binds to CD26 on the surface of 1-LN cells at a site also recognized by plasminogen 2epsilon. As a result, the plasminogen 2epsilon-induced Ca(2+) signaling cascade is inhibited, the expression of matrix metalloproteinase-9 is suppressed, and invasion of Matrigel by 1-LN cells is blocked. Angiostatin 2epsilon is also the only angiostatin glycoform which is able to inhibit in vitro endothelial cell proliferation and tubule formation. These studies suggest that, in addition to its ability to inhibit tumor vascularization, angiostatin 2epsilon may also directly block tumor metastasis.

Duke Scholars

Published In

Exp Cell Res

DOI

ISSN

0014-4827

Publication Date

February 1, 2005

Volume

303

Issue

1

Start / End Page

22 / 31

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Prostatic Neoplasms
  • Plasminogen
  • Matrix Metalloproteinase 9
  • Male
  • Humans
  • Endothelial Cells
  • Dipeptidyl Peptidase 4
  • Cell Movement
  • Biochemistry & Molecular Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gonzalez-Gronow, M., Grenett, H. E., Gawdi, G., & Pizzo, S. V. (2005). Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res, 303(1), 22–31. https://doi.org/10.1016/j.yexcr.2004.09.008
Gonzalez-Gronow, Mario, Hernan E. Grenett, Govind Gawdi, and Salvatore V. Pizzo. “Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.Exp Cell Res 303, no. 1 (February 1, 2005): 22–31. https://doi.org/10.1016/j.yexcr.2004.09.008.
Gonzalez-Gronow M, Grenett HE, Gawdi G, Pizzo SV. Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res. 2005 Feb 1;303(1):22–31.
Gonzalez-Gronow, Mario, et al. “Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.Exp Cell Res, vol. 303, no. 1, Feb. 2005, pp. 22–31. Pubmed, doi:10.1016/j.yexcr.2004.09.008.
Gonzalez-Gronow M, Grenett HE, Gawdi G, Pizzo SV. Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Exp Cell Res. 2005 Feb 1;303(1):22–31.
Journal cover image

Published In

Exp Cell Res

DOI

ISSN

0014-4827

Publication Date

February 1, 2005

Volume

303

Issue

1

Start / End Page

22 / 31

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Prostatic Neoplasms
  • Plasminogen
  • Matrix Metalloproteinase 9
  • Male
  • Humans
  • Endothelial Cells
  • Dipeptidyl Peptidase 4
  • Cell Movement
  • Biochemistry & Molecular Biology